Drug repurposing
Our focus
At Sinfatin, we focus on repositioning marketed medicines for the treatment of central nervous system disorders. We leverage the known safety and efficacy profiles of existing medicinal products and identify new therapeutic applications. This strategy allows us to accelerate the development of effective therapies for unmet medical needs, especially in CNS diseases.
Our main mission is to improve care and quality of life of patients by repositioning safe and effective therapies for neurological conditions. We are committed to the scientific excellence, ethical research and innovative approaches that provide meaningful treatments for those suffering from fatigue and related functional symptoms caused by CNS diseases.
Our vision is to become a leading global force in transforming the therapeutic landscape of CNS diseases.
What we do
At Sinfatin, we work to transform scientific knowledge into new therapeutic solutions for unmet medical needs.
Our main focus is the repurposing of drugs for central nervous system diseases. Through this strategy, we accelerate patient access to safe and effective treatments.
Drug repurposing
At Sinfatin, we research new clinical applications for existing drugs. We specialize in pathologies affecting the CNS, such as spinal cord injury and stroke. This approach allows us to accelerate development, reduce risks, and make effective and safe therapies available to patients more quickly.
Our current project with rimonabant is a clear example of our commitment to improving quality of life through clinical research.
Search for markets and solutions
We identify new products with potential for use in new pathologies and market opportunities for medicines, primarily for neurological diseases, with special attention to countries and sectors where the therapeutic need is greatest and the impact may be most significant.
Development of patents and licenses
We protect our advances by managing patents and licensing our medicines.
This allows us to ensure the commercial viability of each project, facilitating collaboration agreements, technology transfer, or licensing with third parties.
Distribution of medicines
We plan strategies for distribution of repositioned medicines adapted to each phase of clinical development.
Our vision integrates regulatory compliance, logistical efficiency, and collaboration with healthcare stakeholders to ensure that treatments reach the areas of greatest need, especially in the area of neurological diseases.
Rimonabant: clinical development
At Sinfatin, we are leading the clinical development of rimonabant, a selective inhibitor of CNS endocannabinoid (CB1) receptors with broad therapeutic potential. We are currently evaluating its efficacy for the treatment of symptoms such as mental or physical fatigue and walking difficulties associated with conditions such as stroke and spinal cord injury, among others.
By understanding its mechanism of action and its pharmacological and safety profiles, it is possible to accelerate the clinical development of rimonabant, addressing unmet medical needs.
This project represents a promising advance in the search for new therapeutic indications to improve fatigue and related functional symptoms caused by CNS diseases.
We work to improve the lives of those living with central nervous system disorders by mitigating fatigue due to damage to motor systems.
Our commitment is to move toward more effective, safe, and accessible treatments.
